Highlights

04-17 Kailera makes a splash on Nasdaq as anti-obesity drug frenzy continues Zonebourse
04-17 Kailera soars over 60% in Nasdaq debut as weight-loss drug race heats up RE
04-17 Whistling Past Hormuz Zonebourse
04-17 Buy the Dip Zonebourse
04-16 Gerresheimer rebounds sharply on lender support DP
04-16 Lilly says Foundayo pill lowers heart attack, stroke risk in study RE
04-15 GSK plc Receives Additional Marketing Approval for Depemokimab CI
04-15 GoodRx Offering Novo Nordisk's Wegovy HD Weight Loss Drug MT
04-15 European shares flat as investors weigh corporate earnings; Middle East in focus RE
04-14 Novo Nordisk A/S and OpenAI Partner to Transform How Medicines Are Discovered and Delivered CI
04-14 FDA seeks additional safety data from Lilly on newly approved weight-loss pill RE
04-14 Exchange-Traded Funds, Equity Futures Lower Pre-Bell Tuesday Amid Hopes of Long-Term US-Iran Truce MT
04-14 S&P 500 Rebound, Optimism for US-Iran Deal Move US Equity Futures Higher Pre-Bell MT
04-14 Betting on Restraint Zonebourse
04-14 Novo Nordisk Receives UK Regulator Approval for Single-Dose 7.2mg of Wegovy MT
04-14 European Midday Briefing : Shares Rise, Oil Slips on Peace Talks Hopes DJ
04-14 Novo Nordisk Partners with OpenAI to Boost Drug Development, Delivery MT
04-10 Wall Street Gets a CPI Lifeline Zonebourse
04-10 Lifemd Inc Announces Foundayo Orforglipron Oral Glp-1 Pill for Weight Management CI
04-09 Novo Nordisk Says EU Regulator Approves Updated Wegovy Injection MT
04-09 Novo Nordisk's Updated Product Storage for Wegovy Injection Gets EU Approval MT
04-09 Ema approves Novo Nordisk's Wegovy injection for 48 hours controlled-temperature delivery RE
04-09 Novo Nordisk A/S Receives Ema Approval for Controlled-Temperature Delivery of Wegovy Injection in Europe CI
04-07 Lexaria Bioscience Corp Recognizes Eli Lilly and Company Foundayo Drug Approval CI
04-07 Novo Nordisk Launches Higher Dose Wegovy in US With Pricing Below Eli Lilly's Zepbound MT
No results for this search